Track market-moving stories before they get noisy

Media Release

COPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026

Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC)
Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a first-line treatment for patients with metastatic colorectal cancer harboring a KRAS G12D mutation, an area with substantial unmet medical need.

“This collaboration supports our broader development strategy for petosemtamab as we explore its potential across treatment settings and in novel combinations,” said Judith Klimovsky, M.D., Executive Vice President and Chief Development Officer, Genmab. “Partnering with Incyte enables us to evaluate this investigational combination in patients with KRAS G12D-mutated metastatic colorectal cancer, reflecting our commitment to research collaborations aimed at expanding potential treatment options for more patients.”

“Metastatic colorectal cancer remains difficult-to-treat, underscoring the importance of evaluating novel combinations grounded in complementary scientific approaches with the potential to enhance efficacy,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. “Our collaboration with Genmab will explore the potential of combining KRAS G12D inhibition with LGR5-targeted EGFR inhibition and standard-of-care chemotherapy, with the goal of advancing a new first-line treatment approach for patients with metastatic colorectal cancer.”

Under the collaboration, Genmab will conduct the Phase 1/2 study evaluating petosemtamab in combination with INCB161734 and standard-of-care chemotherapy in patients with KRAS G12D-mutated mCRC in the first-line setting. Incyte will co-fund the study and provide clinical supply of INCB161734.

KRAS mutations occur in approximately 40% of colorectal cancers, with G12D being the most common KRAS mutation. These cancers are associated with poor prognosis, underscoring the need for new treatment approaches. The collaboration reflects a shared focus on investigating whether agents with distinct and potentially complementary mechanisms, combined with standard-of-care chemotherapy, may offer a path toward a new treatment option for patients with KRAS G12D-mutated metastatic colorectal cancer.

About Petosemtamab (GEN1158)
Petosemtamab is an investigational human IgG1-based bispecific antibody targeting the EGFR and the LGR5 and designed to support multiple anti-tumor mechanisms. It inhibits EGFR-mediated signaling by engaging a unique site on the receptor to prevent ligand binding. In addition, petosemtamab triggers EGFR degradation in cancer stem-like cells expressing both EGFR and LGR5. Petosemtamab is also engineered to enhance innate immune-mediated activity through interactions with macrophages and natural killer cells. It is currently being investigated in head and neck squamous cell carcinoma (HNSCC) and other solid tumors, including colorectal cancer (CRC). Petosemtamab is being evaluated in combination with chemotherapy in two Phase 3 trials in first- and second-line RAS/BRAF wild-type metastatic CRC. Please visit https://clinicaltrials.gov/ for more information.

About INCB161734
INCB161734 is an investigational, novel, selective and orally bioavailable small molecule ON/OFF KRAS G12D inhibitor. KRAS is one of the most frequently altered oncogenic drivers across solid tumors, and the KRAS G12D mutation is among the most common KRAS alterations, occurring in approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases and approximately 15% of colorectal cancer (CRC) cases.

INCB161734 is being evaluated in the global Phase 3 DAWN-303 (NCT07522073) study which is currently enrolling patients with previously untreated KRAS G12D-mutated pancreatic ductal adenocarcinoma (PDAC) to further evaluate the efficacy and safety of INCB161734 in combination with standard-of-care (SoC) chemotherapy.

INCB161734 is also being evaluated as a monotherapy and in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel [GEMNabP] or modified FOLFIRINOX [mFOLFIRINOX]), in an ongoing open-label Phase 1 study across KRAS G12D-mutated solid tumors (NCT06179160).

About Genmab 
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com or follow us on LinkedIn, X, Facebook and Instagram.

About Incyte®
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Genmab Contacts

Media:        
Jyoti Sharma, Director, Global Communications & Corporate Affairs
T: +1 609 480 9844; E: [email protected]

Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: [email protected]

Incyte Contacts

Genmab Forward-Looking Statements
This Media Release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.

Incyte Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding Incyte’s clinical trial collaboration with Genmab; the design, initiation, timing, conduct, sponsorship and funding of the planned studies; the potential presented by INCB161734, petosemtamab and the combination of these investigational therapies with standard-of-care chemotherapy; the potential for the combination to provide a new treatment option for patients with first-line KRAS G12D-mutated metastatic colorectal cancer; expectations regarding the initiation, timing, progress and results of ongoing and planned clinical trials for INCB161734; whether or when INCB161734, petosemtamab or any combination regimen will be approved or commercially available for use in humans anywhere in the world; Incyte’s oncology portfolio and development strategy; and Incyte’s aspirations and goals as set forth under the heading “About Incyte.”

Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including whether preclinical or early clinical results will be replicated in later-stage or larger clinical trials; the sufficiency of clinical trial data to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and to enroll subjects in accordance with planned schedules; changes in clinical development plans; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and regulatory approval; the efficacy or safety of Incyte’s products and product candidates; Incyte’s ability to successfully develop and commercialize its product candidates; Incyte’s reliance on third parties and collaboration partners, including with respect to the planned studies described herein; the availability and effectiveness of competing treatments; Incyte’s ability to obtain and maintain protection of intellectual property for its products and technology; greater than expected expenses, including expenses relating to clinical development, litigation or strategic activities; and those risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025 and its quarterly report on Form 10-Q for the quarter ended June 30, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements.

102426 MR13 Genmab Incyte CRC

Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026PR Newswire

GUANGZHOU, China, Oct. 24, 2026

, /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, today announced the presentation of clinical data for BAT8008, a TROP2-targeted antibody-drug conjugate (ADC), in combination with BAT1308, an anti-PD-1 monoclonal antibody, at the 2026 European Society for Medical Oncology (ESMO) Congress. Professor Shaodong Hong of Sun Yat-sen University Cancer Center delivered a rapid oral presentation highlighting results from the combination regimen in patients with non-small cell lung cancer (NSCLC). Further details are available on Bio-Thera's official website.

In the first-line, mutation-negative NSCLC population (N=104), treatment with BAT8008 in combination with BAT1308 achieved an objective response rate (ORR) of 61.2% and a median progression-free survival (PFS) of 12.42 months. In the non-squamous NSCLC subgroup, the ORR was 65.2%, while median PFS had not yet been reached at the time of analysis. The combination demonstrated a manageable safety profile consistent with the known safety characteristics of the individual agents, with no new safety signals identified.

"We are very encouraged by these Phase 2 results evaluating BAT8008 in combination with BAT1308 as a first-line treatment for advanced non-small cell lung cancer", said Shengfeng Li, CEO of Bio-Thera Solutions. "The findings support the potential of this combination approach in First Line NSCLC and reinforce our commitment to advancing innovative oncology therapies for patients with significant unmet medical needs."

Lung cancer remains a major global health challenge, and NSCLC accounts for the majority of lung cancer cases. Patients with advanced NSCLC who lack actionable genomic alterations continue to face significant treatment challenges, despite advances in immunotherapy and chemoimmunotherapy. New treatment strategies that can improve clinical outcomes while maintaining a manageable safety profile remain an important area of oncology research.

TROP2-targeted ADCs combine tumor-directed delivery of cytotoxic payloads with the potential to modulate the tumor microenvironment. When combined with PD-1 blockade, this approach may offer complementary mechanisms of action, providing a rationale for clinical investigation in NSCLC. The clinical findings presented at ESMO 2026 support further evaluation of BAT8008 in combination with BAT1308 as a potential treatment option for patients with NSCLC.

About Bio-Thera Solutions:

Bio-Thera Solutions, Ltd., a leading innovative, global biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in next generation antibody discovery and engineering, the company has advanced multiple candidates into late-stage development, including six approved products: QLETLI® (adalimumab) and BETAGRIN® (bevifibatide citrate) Injection in China, STARJEMZA® (ustekinumab) in the US and USYMRO® (ustekinumab) in the EU, TOFIDENCE®/BAT1806 (tocilizumab) and AVZIVI® (bevacizumab-tnjn) in the US and in the EU, a/k/a POBEVCY® in China, and GOTENFIA® (golimumab) in the EU and IMMGOLIS™ (golimumab-sldi) in the US. In addition, the company has more than 20 promising candidates in clinical trials, focusing on immuno-oncology in the post-PD-1 era and targeted therapies such as antibody-drug conjugates (ADCs). For more information, please visit www.bio-thera.com/en/ or follow us on X (@bio_thera_sol) and WeChat (Bio-Thera).

Bio-Thera Cautionary Note Regarding Forward-Looking Statements

This news release contains certain forward-looking statements relating to BAT8008, BAT1308 or the product pipelines in general of Bio-Thera Solutions. Readers are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. The forward-looking statements include, among others, those containing "could," "may," "should," "will," "would," "anticipate," "believe," "plan," "promising," "potentially," or similar expressions. They reflect the company's current views with respect to future events that are based on what the company believes are reasonable assumptions in view of information currently available to Bio-Thera Solutions, and are not a guarantee of future performance or developments. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including, but not limited to, risks and uncertainties inherent in pharmaceutical research and development, such as the uncertainties of pre-clinical and clinical studies. Other risks and uncertainties include challenges in obtaining regulatory approvals, manufacturing, marketing, competition, intellectual property, product efficacy or safety, changes in global healthcare situation, changes in the company's financial conditions, and changes to applicable laws and regulations, etc. Forward-looking statements contained herein are made only as of the date of their initial publication. Unless required by laws or regulations, Bio-Thera Solutions undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, changes in the company's views or otherwise.

Bio-Thera Contact:
Bert E. Thomas IV
Phone: +1.410.627.1734
Email: [email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-thera-announces-promising-clinical-data-for-bat8008-in-combination-with-bat1308-in-first-line-non-small-cell-lung-cancer-at-esmo-2026-302918492.html

SOURCE Bio-Thera Solutions, Ltd

Bilanol/iStock via Getty Images

In a previous article we showed that at private timberland values, Weyerhaeuser’s (WY) 9.74 million owned acres are worth $26.2B which demonstrates a substantial gap between asset value and WY’s valuation.

Since then, new data has come out showing that timberland values have continued to rise while WY’s stock price has continued to fall. It has created a historically wide disconnect between public and private pricing with WY trading at 50% of net asset value.

We shall begin by showing the disparate movement of underlying asset value with WY’s stock price and follow with a look at what a 50% discount to NAV means in this asset class with WY’s capital structure.

Value up – price down Timberland value is best measured by actual transactions that take place. FRC and Fastmarkets compiled transaction data to show average transaction price per acre over time.

Forest Resource Consultants

Source

Transaction values generally rose from about $1,800 per acre in 2018 to just over $2,500 per acre in 2025.

That is roughly what one would expect in an inflationary period. Timberland values have continued to rise in 2026. NCREIF reports timberland appreciation of 3.28% year-over-year in 1Q26 and another 0.61% in 2Q26

NCREIF

In 2026 timberland values have been rising at a pace slower than inflation. This is likely due to rising interest rates which mathematically pull down the value of long duration assets.

Nonetheless, timberland values are up in 2026. Contrast that with WY’s stock price down 20%.

SA

WY was already steeply discounted to asset value in 2025. I thought it was a great deal buying it at 66% of NAV.

So far, I have been quite wrong on the stock price. However, I have mostly been right on the fundamentals. Key earnings metrics are showing excellent current year and future growth.

Below are the consensus estimates of Wall Street analysts covering WY:

S&P Global Market Intelligence

2026 is coming in substantially higher than 2025 in FFO, AFFO, revenue and EBITDA. Growth is forecast to accelerate into 2028 with FFO rising 83% from 2025 levels. 2028 EBITDA is roughly 70% higher.

Good things are happening at the company. They have innovative products like TimberStrand and operate mills and timberlands with superior efficiency to competitors.

Mill curtailments across Canada and smaller operators in the U.S. are materially reducing competition which has kept lumber prices stable despite the slowdown in housing driven by high mortgage rates.

Tradingeconomics

7.5% mortgage rates are a tough operating environment for the entire housing industry. It seems the market has painted the industry with a broad bearish brush, selling nearly all participants in unison.

The selloff has been agnostic to valuation and agnostic to individual company fundamentals. In my opinion, WY selling down an additional 20% in 2026 from an already highly discounted level has taken it to an absurd discount.

Profound mispricing

WY’s consensus NAV is $37.16

S&P Global Market Intelligence

At today’s $18.84, it is trading at 50.7% of NAV.

REITs historically trade mostly between 90% and 105% of NAV. Occasionally, something slips through the cracks or has underlying problems that can result in substantially deeper discounting.

We have observed 50% of NAV magnitude of discounting primarily in the following types of companies:

Microcaps Extremely high leverage (80%+ capital structure is debt/preferred) Misaligned management (RMR companies, Ashford companies) Troubled asset class (office and malls) WY stands out because it distinctly doesn’t have the problems above.

Market share leader as the largest timberland owner in the U.S. Large cap Investment grade balance sheet (BBB) Respected management that outperforms on key operating metrics Perhaps the market is viewing and pricing timberland as a troubled asset class. I think there is a big difference between a cyclical downturn and structural damage.

Lumber is absolutely in a cyclical downturn, but I haven’t heard any legitimate talk of it being a permanently impaired industry. Eventually, houses will have to be built as there is already a housing shortage.

50% of NAV in a historical context In order for the discount at which WY trades to make sense there would have to be legitimate risk that timberland values could drop enough to close the gap in that direction.

Timber/lumber is a highly stable industry that has been around for centuries and through dozens of business cycles. I want to examine what a 50% discount means in a stable industry, so we shall look at some of the most severe downturns in history to see what happened to asset values.

Housing bubble – home prices declined 18.9% peak to trough.

FRED

Prices peaked at an indexed level of 380 in 2007 and dropped to a 308 trough in 2012. That is an 18.9% decline from peak to trough.

The USDA documents the largest agricultural land value decline of the century at 37% and it happened during the Great Depression which hit simultaneously with the physical damage of the Dust Bowl.

“Agricultural land values saw the largest percentage declines of the century in the early 1930s, the beginning of the Great Depression. Agricultural land values dropped 37 percent over a period of 3 years and remained between $30 and $33 per acre throughout the 1930s.”

In both cases, asset values rebounded sharply and sustainably after the trough.

I posit that what WY is dealing with is a run-of-the-mill housing recession brought on by a sharp rise in mortgage rates.

It is nowhere near the severity of the housing bubble popping in the Great Financial Crisis or the Dust Bowl amidst the Great Depression.

Even in such severe cases, the 50% discount at which WY trades would be enough to more than offset the drawdowns in asset value. Note that timberland values have actually risen so far in 2026. They may not decline at all in this cycle as land tends to be a great asset class in a higher than target inflation environment.

When the housing cycle eventually turns, WY will be the largest operator in an environment where competition has been substantially shrunk due to curtailments. It takes years for those competing mills to come back online, and WY did not have to shut down operations due to higher operating margins. WY has been strongly EBITDA positive through the entire downturn, positioning it to capture significant market share.

Risks to WY I think there is a decent chance WY misses estimates in 3Q26 due to the timing of changes in interest rates. Through the first half of 2026, interest rates and mortgage rates were stable.

Suddenly, in 3Q26, mortgage rates shot up to 7.5%

Tradingeconomics

This likely had an acute depressive impact on housing activity.

WY and analysts were forecasting a somewhat weak environment, but I don’t think guidance was anticipating the sharp rise in rates. Lumber prices held up, but volume suffered.

In terms of overall valuation, I don’t think a weak 3Q26 is all that impactful. However, a miss could cause further damage to WY’s stock price in the near term.

The bottom line

WY is trading at profoundly cheap levels that don’t make sense for a company of its caliber. While it is difficult to predict the cadence of recovery in stock price, I think buying at these levels will eventually be rewarded with strong returns as the stock price eventually moves toward NAV.

BDCs trade at a steep discount, but the risks the bears talk about most may not be the ones that matter. One overlooked risk, hidden in loans made years ago, is already hurting several well-known names. Some of the most popular BDCs may be more exposed than their results suggest, and the moment of truth is getting closer.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In The Ensign Group To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in The Ensign Group between February 10, 2022 and June 18, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 24, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Ensign Group, Inc. (""The Ensign Group" or the "Company") (NASDAQ: ENSG) and reminds investors of the December 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

SummaryExlService is rated a Strong Buy, as AI adoption accelerates revenue growth and the disruption narrative has compressed its valuation to 18x forward P/E.EXLS's data- and AI-led business, now 61% of revenue, is growing at 30% YoY, offsetting a purposeful decline in legacy digital operations.EXLS addresses sovereignty and liability barriers in regulated industries, enabling enterprise AI integration and driving outcome-based revenue with high retention.My projections suggest EXLS could double by end-2027 if AI-led growth persists and the multiple re-rates, while the bear case downside is -32%. sitox/E+ via Getty Images

Investment Thesis Over the first half of 2026, the market priced ExlService (EXLS) as a severe AI casualty. If we take a look at this chart, we can see it tells a story of two parts: in February 2026, the whole consulting/data management

341 Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of EXLS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Atlatl Advisers LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ: ILMN) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 35,165 shares of the life sciences company's stock, valued at approximately $9,624,000. Illumina

Chemours has been sued for securities fraud after its stock plummeted 18.63% because Chemours allegedly misrepresented the strength of demand for its Opteon products.

New York, New York--(Newsfile Corp. - October 24, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Chemours Company (NYSE: CC) and certain of the company's senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Chemours, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.

Key Details of the Chemours ($CC) Class Action:

Lead Plaintiff Deadline: December 7, 2026Alleged Misconduct: Securities fraud alleging Chemours misrepresented the strength of demand for its Opteon products Stock Drop: August 5, 2026 – 18.63% Stock DropCourt: U.S. District Court for the District of DelawareAction: Contact BFA Law to discuss your rightsInvestors have until December 7, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Chemours securities. The class action is pending in the U.S. District Court for the District of Delaware. It is captioned Darcy v. The Chemours Company, No. 26-cv-1299.

Why is Chemours Being Sued for Securities Fraud?

Chemours offers a range of industrial and specialty chemical products, including Opteon, a set of refrigeration chemicals with a reduced ozone-depletion footprint. In late 2020, Congress enacted the U.S. AIM Act, which directed the EPA to oversee the transition to alternative refrigerants that present a lesser impact to the ozone layer.

According to the complaint, Chemours stated that continued adoption of the AIM Act drove sustained growth for its Opteon products. Chemours stated that the "sustained double-digit" Opteon expansion would be "driven by the continued regulatory adoption" of the AIM Act. What's more, Chemours provided 2026 net sales guidance of 3% to 5% growth and 2026 adjusted EBITDA guidance of $800M – $900M, driven by "higher . . . demand" in its Opteon segment.

As alleged, Chemours failed to disclose that customers were already oversupplied with Opteon products because of the AIM Act transition, leading to an "oversupplied channel heading into 2026."

Why did Chemours's Stock Drop?

On August 4, 2026, Chemours announced Q2 2026 financial results, revealing an approximately 1% year-over-year decrease in net sales and cutting 2026 adjusted EBITDA guidance by about 11% (to $775M – $825M from $800M – $900M). Chemours also revealed that customers had "built additional inventory" of Opteon products the prior year, that aftermarket channels had been filled, and that Chemours was selling into an "oversupplied channel heading into 2026."

On this news, Chemours's stock dropped $3.34 per share, or 18.63%, from a closing price of $17.93 per share on August 4, 2026, to $14.59 per share on August 5, 2026.

Click here for more information: https://www.bfalaw.com/cases/chemours-class-action-lawsuit.

What Can You Do?

If you invested in Chemours, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/chemours-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360, and "SuperLawyers" by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."

BFA's notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/chemours-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320500

Source: Bleichmar Fonti & Auld

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Axxcess Wealth Management LLC increased its holdings in Valero Energy Corporation (NYSE: VLO) by 50.1% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,064 shares of the oil and gas company's stock after acquiring an additional 1,357

Boomfish Wealth Group LLC boosted its holdings in shares of KLA Corporation (NASDAQ: KLAC) by 21.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,703 shares of the semiconductor company's stock after purchasing an additional 4,330 shares during

Atlatl Advisers LLC acquired a new position in shares of Marvell Technology, Inc. (NASDAQ: MRVL) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 17,860 shares of the semiconductor company's stock, valued at approximately $4,719,000. Marvell Technology makes up

The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rate both quantitatively and qualitatively and select the top 10 names from an initial list of nearly 500 dividend stocks. The final list of ten stocks is chosen based on sector diversity, high-growth quality scores, and positive momentum, and is suitable for investors in the accumulation phase.

E. Ohman J or Asset Management AB acquired a new stake in ATI Inc. (NYSE: ATI) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 5,061 shares of the basic materials company's stock, valued at approximately $959,000. Several other hedge funds have

Brookstone Capital Management purchased a new position in Builders FirstSource, Inc. (NYSE: BLDR) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 185,217 shares of the company's stock, valued at approximately $10,559,000. Brookstone Capital Management owned approximately 0.17% of Builders

Shares of Atlassian Corporation PLC (NASDAQ:TEAM – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twenty-nine brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-four have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $213.35.

Several research firms have commented on TEAM. Guggenheim upped their price objective on shares of Atlassian from $165.00 to $280.00 and gave the company a “buy” rating in a report on Monday. FBN Securities reiterated an “outperform” rating and issued a $170.00 target price on shares of Atlassian in a research note on Monday, August 10th. Oppenheimer boosted their price target on shares of Atlassian from $200.00 to $275.00 and gave the company an “outperform” rating in a research report on Thursday. BMO Capital Markets upped their price target on shares of Atlassian from $95.00 to $175.00 and gave the company an “outperform” rating in a research note on Friday, August 7th. Finally, Royal Bank Of Canada upped their price target on shares of Atlassian from $215.00 to $235.00 and gave the company an “outperform” rating in a research note on Monday, October 12th.

Get Our Latest Stock Analysis on Atlassian

Insider Buying and Selling at Atlassian In other Atlassian news, CRO Brian Duffy sold 1,851 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $172.45, for a total transaction of $319,204.95. Following the sale, the executive owned 218,223 shares in the company, valued at $37,632,556.35. This represents a 0.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James Chuong sold 9,054 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $172.45, for a total value of $1,561,362.30. Following the completion of the transaction, the chief financial officer directly owned 279,218 shares of the company’s stock, valued at $48,151,144.10. The trade was a 3.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 22,475 shares of company stock valued at $3,822,643 in the last 90 days. 37.63% of the stock is currently owned by company insiders. Institutional Trading of Atlassian A number of hedge funds and other institutional investors have recently made changes to their positions in TEAM. Activest Wealth Management grew its holdings in Atlassian by 372.4% during the 3rd quarter. Activest Wealth Management now owns 137 shares of the technology company’s stock valued at $25,000 after buying an additional 108 shares in the last quarter. Reyes Financial Architecture Inc. bought a new stake in shares of Atlassian during the third quarter valued at about $49,000. Fortitude Family Office LLC increased its position in shares of Atlassian by 23.0% during the third quarter. Fortitude Family Office LLC now owns 289 shares of the technology company’s stock valued at $52,000 after buying an additional 54 shares during the period. Physician Wealth Advisors Inc. increased its position in shares of Atlassian by 142.4% during the third quarter. Physician Wealth Advisors Inc. now owns 337 shares of the technology company’s stock valued at $60,000 after buying an additional 198 shares during the period. Finally, Manning & Napier Advisors LLC purchased a new stake in shares of Atlassian in the second quarter worth about $27,000. 94.45% of the stock is currently owned by institutional investors.

Atlassian Price Performance Atlassian stock opened at $227.61 on Friday. The business’s 50 day simple moving average is $191.25 and its 200 day simple moving average is $125.51. Atlassian has a 12 month low of $56.01 and a 12 month high of $229.96. The company has a market cap of $57.76 billion, a price-to-earnings ratio of -1,197.95, a PEG ratio of 23.80 and a beta of 1.22. The company has a current ratio of 0.78, a quick ratio of 0.78 and a debt-to-equity ratio of 0.93.

Atlassian (NASDAQ:TEAM – Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The technology company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.37. Atlassian had a positive return on equity of 20.99% and a negative net margin of 0.82%. The company had revenue of $1.77 billion during the quarter, compared to the consensus estimate of $1.66 billion. During the same quarter in the prior year, the company earned $0.98 EPS. The firm’s quarterly revenue was up 27.6% compared to the same quarter last year. Sell-side analysts forecast that Atlassian will post 0.69 EPS for the current year.

Atlassian Company Profile (Get Free Report)

Atlassian Corporation develops collaboration, project-management and workflow software for technology, business and service teams. Its products are designed to help organizations plan projects, manage software development, coordinate work and share knowledge across departments.

Its product portfolio includes Jira for project and issue tracking, Confluence for team collaboration and knowledge management, Jira Service Management for IT and enterprise service workflows, Trello for organizing tasks and projects, Loom for video messaging and screen recording, and Bitbucket for source-code management and collaboration.

See Also Five stocks we like better than Atlassian Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat

Receive News & Ratings for Atlassian Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atlassian and related companies with MarketBeat.com's FREE daily email newsletter.

Carderock Capital Management Inc. trimmed its stake in shares of Quanta Services, Inc. (NYSE: PWR) by 10.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,526 shares of the construction company's stock after selling 2,095 shares during the quarter.

Boomfish Wealth Group LLC bought a new stake in shares of Old Republic International Corporation (NYSE: ORI) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 18,642 shares of the insurance provider's stock, valued at approximately $696,000. Several other institutional investors have

Crossmark Global Holdings Inc. raised its holdings in shares of Ryder System, Inc. (NYSE: R) by 10.5% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 22,348 shares of the transportation company's stock after acquiring an additional 2,125 shares during the quarter.

Boomfish Wealth Group LLC grew its position in Monolithic Power Systems, Inc. (NASDAQ: MPWR) by 74.1% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,722 shares of the semiconductor company's stock after purchasing an additional 733 shares during the quarter.

Fifth Third Wealth Advisors LLC raised its position in Axon Enterprise, Inc (NASDAQ: AXON) by 13,721.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 158,812 shares of the biotechnology company's stock after acquiring an additional 157,663 shares during the quarter. Axon Enterprise

Three BDC lenders are dangling yields above 13%, but a sky-high payout on one of them comes with a trail of red flags that most income investors miss until it is too late to get out whole.

Business development companies (BDCs) lend to midsize private businesses that are too small to tap the bond market. To avoid corporate income tax, they have to pass most of their taxable income through to shareholders, so their yields sit well above almost everything else on the income menu. In this group of three large lenders, even the lowest yield is 13.1%. A yield that high usually signals the market doubts the payout will last, so this bundle prioritizes safety. For each name, we look at how well net investment income (NII) covers the dividend, how many loans have stopped paying, and where the stock trades against book value.

FS KKR Capital: A 21.3% Yield Flashing Warning Lights FS KKR Capital (NYSE:FSK | FSK Price Prediction) yields 21.3%, the highest of the three. Read that number as a warning before you read it as an opportunity. When a lender’s yield goes above 20%, the share price is usually telling you the market expects more trouble. The payout history supports that reading. FS KKR paid $0.70 in each quarter of 2025. In 2026, the payments fell to $0.48, $0.42, and $0.44. The trailing 12-month total is $2.04, compared with an annualized forward figure of $1.76.

Coverage: Second-quarter NII came in at $0.44 per share, exactly matching the $0.44 third-quarter distribution. An outside factor helped that match: KKR is giving up 50% of its subordinated income incentive fee for four quarters starting in Q2. Before the cut and the waiver, first-quarter adjusted EPS of $0.41 did not cover the $0.48 distribution. The company also said it may pay distributions from sources other than NII.

The trailing EPS of -1.41 is the second warning sign. GAAP earnings include realized and unrealized losses on the loan book. In the first quarter alone, FS KKR posted a GAAP loss of $1.57 per share on $558 million in net losses, with another $154 million in Q2. Negative earnings mean the loan book is losing value faster than interest income can replace it. A smaller asset base produces less NII in future quarters, which is the money that pays your dividend.

Credit and book value: Nonaccruals (loans that have stopped paying) improved to 3.8% of the portfolio at fair value from 4.2%, but they are still 7.1% at amortized cost. Debt-to-equity fell to 127% from 138%, putting it back within the target range. The stock trades around $10.44 against a NAV of $18.30, and NAV was $20.89 at the end of 2025. Shares are down 20.19% year to date.

Bull case: KKR has committed its own capital. It bought $150 million of convertible preferred stock and completed a $150 million tender offer at $11.00 per share. FS KKR has also repurchased about 3.7 million shares at roughly $10.73, well below NAV. In the Q2 release, CEO Michael C. Forman said FSK “reduced net leverage to within our target range, and made progress reducing our non-accrual assets.”

Risk: The fee waiver is temporary, and the portfolio is shrinking. Q2 sales and repayments totaled $1.33 billion against $590 million in purchases. When the waiver ends, a smaller book must cover the payout on its own.

Blue Owl Capital Corporation: A Reset Dividend With Room to Spare Blue Owl Capital Corporation (NYSE:OBDC) yields 14.4%. Management cut the base dividend to $0.31 from $0.37 to match the company’s go-forward earnings power, and it still pays occasional supplementals. The latest supplemental was $0.02, paid 2026-09-15. The annualized forward amount of $1.24 is below the trailing total of $1.38, so budget your income around the lower base.

Coverage: The adjustment is working. Second-quarter adjusted NII of $0.34 beat the $0.32 consensus and covered the $0.31 base with room for a supplemental. In the first quarter, by contrast, NII of $0.31 fell short of the old $0.37 base. CEO Craig W. Packer pointed to “a 9.6% annualized return on adjusted net investment income and healthy dividend coverage.”

Credit and book value: Nonaccruals rose to 2.8% of the portfolio at cost, up from 2.0%. The balance sheet is the best part of the story. Net debt-to-equity is 1.11x, a two-year low. Moody’s upgraded the company to Baa2 in January, and it issued $800 million of unsecured debt in Q2. The $14.96 billion portfolio spans 229 companies. The stock trades near $10.06 against a NAV of $14.26, and management has bought back about $35 million of stock in each of the past two quarters. Sentiment around the wider Blue Owl platform is still weak: the Wall Street Journal recently reported that the company’s share price hasn’t budged despite its founders’ promise of a comeback.

Bull case: An investment-grade rating, low leverage, and a base dividend that fits current earnings make this the clearest coverage story of the three. Shares are down 11.28% year-to-date, so the discount to book is wider than it was in January.

Risk: Earning power is under pressure. New commitments are yielding 8.7%, down from 9.7% a year ago, and Q2 repayments of $747 million far topped financings of $219 million.

Blackstone Secured Lending Fund: Best Loan Book, Thinnest Cushion Blackstone Secured Lending Fund (NYSE:BXSL) yields 13.1%, and it has the steadiest payout record in this group. It has paid $0.77 every quarter from the 2023-09-28 ex-dividend date through 2026-09-30, and the latest payment is scheduled for 2026-10-23, which is today.

Coverage: This is the weak spot. Second-quarter NII of $0.75 covered 97% of the dividend. Coverage has slipped each quarter, from 106% to 104% to 100% to its current level, while NII per share fell from $0.82 as base rates came down.

Credit and book value: The portfolio is the highest quality of the three. It is 96.8% first-lien senior secured and 96.3% floating rate, and 93.2% of income comes from cash interest. Nonaccruals are 1.8% at fair value and 3.6% at amortized cost, up from historically low levels. The all-in cost of debt is 5.05%, and the fund issued $650 million of 2031 notes and $400 million of 2029 notes. Moody’s rates it Baa2 with a negative outlook. The stock trades near $23.76 against a NAV of $25.53, the smallest discount to book in this group. NAV was $27.33 a year ago.

The bull case: the market believes this book more than the others. Shares are up 1.92% over the past year while FS KKR and Blue Owl fell by double digits. Brad Marshall said the fund had “no new assets placed on non-accrual” in Q2, and that the portfolio is “underpinned by stable EBITDA growth across our borrowers.”

Risk: If rates keep falling, NII will probably keep drifting lower. Two more quarters below full coverage would put pressure on the board to cut the $0.77 payout.

Which Over-13% Payout Holds Up Best Blue Owl’s adjustment-based dividend of $0.31 looks like the most durable of the three. It is covered by $0.34 of adjusted NII, backed by the company’s lowest leverage in two years, plus an investment-grade rating. Blackstone Secured Lending has the clearest loan book, but at 97% coverage, its long-steady payout leaves little room for error. FS KKR pays the biggest check, and its 21.3% yield, negative trailing EPS, and temporary fee waiver all point to it being the least secure of the three (the same cluster of red flags we broke down in a free guide to spotting dividend traps before the cut).

Contact [email protected] for any questions or corrections.

Carderock Capital Management Inc. boosted its stake in shares of Eaton Corporation, PLC (NYSE:ETN – Free Report) by 22.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,197 shares of the industrial products company’s stock after acquiring an additional 2,037 shares during the quarter. Carderock Capital Management Inc.’s holdings in Eaton were worth $4,811,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Security National Bank of SO Dak acquired a new stake in shares of Eaton during the second quarter worth $26,000. Manning & Napier Advisors LLC purchased a new position in Eaton in the 2nd quarter valued at $27,000. Curry Webb Wealth Management LLC purchased a new position in Eaton in the 3rd quarter valued at $29,000. Boreal Capital Management LLC acquired a new position in Eaton in the 1st quarter valued at $33,000. Finally, North Point Portfolio Managers Corp OH acquired a new position in Eaton in the 3rd quarter valued at $34,000. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Eaton Here are the key news stories impacting Eaton this week:

Positive Sentiment: Analysts continue to raise their earnings outlook. Zacks lifted its fourth-quarter 2026 EPS estimate to $4.04 from $4.03, while Erste Group raised its fiscal 2026 estimate to $13.59 and fiscal 2027 forecast to $16.32. These revisions suggest expectations for continued growth in Eaton’s higher-margin electrical and data-center businesses. Eaton earnings estimate revisions Positive Sentiment: Eaton was highlighted for its energy-efficient electrical products and recognized by IBD as one of the Most Sustainable Companies for a second consecutive year. Its focus on efficient power infrastructure may benefit from expanding electricity and data-center demand. Eaton sustainable profits Neutral Sentiment: Eaton has scheduled its next results for November 3. Investors will look for confirmation of its current fiscal 2026 EPS guidance of $13.40–$13.60 and indications that demand from data centers and electrical infrastructure remains strong. Eaton schedules November 3 results Negative Sentiment: Baird lowered its price target for ETN to $485 from $500. Although the revised target remains well above recent trading levels, the cut can weigh on sentiment, particularly with the stock trading below its 50-day and 200-day moving averages. Baird cuts Eaton price target Negative Sentiment: The shares recently fell 6.33% in one session, indicating broad near-term selling pressure. With quarterly results approaching and valuation still elevated at roughly 37 times earnings, investors may be locking in gains or reducing exposure until Eaton reports. Eaton shares decline more than the market Eaton Trading Down 0.8% Shares of ETN opened at $366.12 on Friday. Eaton Corporation, PLC has a twelve month low of $311.92 and a twelve month high of $478.00. The company has a current ratio of 1.24, a quick ratio of 0.79 and a debt-to-equity ratio of 0.91. The firm has a market capitalization of $142.20 billion, a P/E ratio of 37.25, a PEG ratio of 2.14 and a beta of 1.13. The firm’s 50-day moving average is $415.65 and its two-hundred day moving average is $411.02. Eaton (NYSE:ETN – Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The industrial products company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.08 by $0.07. The company had revenue of $8.53 billion during the quarter, compared to the consensus estimate of $8.16 billion. Eaton had a net margin of 12.75% and a return on equity of 24.58%. The company’s revenue for the quarter was up 21.4% on a year-over-year basis. During the same period last year, the firm earned $2.95 EPS. Eaton has set its Q3 2026 guidance at 3.460-3.560 EPS and its FY 2026 guidance at 13.400-13.600 EPS. On average, research analysts predict that Eaton Corporation, PLC will post 13.59 earnings per share for the current fiscal year.

Insider Buying and Selling at Eaton In other news, insider Heath Monesmith sold 18,036 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $458.04, for a total value of $8,261,209.44. Following the completion of the transaction, the insider owned 50,368 shares in the company, valued at $23,070,558.72. This trade represents a 26.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Gerald Johnson purchased 130 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were purchased at an average cost of $455.90 per share, with a total value of $59,267.00. Following the purchase, the director directly owned 1,829 shares in the company, valued at approximately $833,841.10. The trade was a 7.65% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes A number of equities analysts have commented on the stock. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Eaton from $493.00 to $521.00 and gave the stock a “buy” rating in a research report on Wednesday, September 30th. Rothschild & Co Redburn lifted their target price on shares of Eaton from $386.00 to $403.00 and gave the company a “neutral” rating in a report on Wednesday, September 30th. Evercore boosted their price target on shares of Eaton from $502.00 to $515.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 11th. Argus lifted their price objective on Eaton from $475.00 to $528.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Finally, BMO Capital Markets boosted their target price on Eaton from $477.00 to $487.00 and gave the stock an “outperform” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $484.10.

Get Our Latest Report on Eaton

About Eaton (Free Report)

Eaton Corporation plc is a global intelligent power management company that helps businesses, utilities, data centers, manufacturers and other organizations manage electrical, hydraulic and mechanical power more safely, efficiently and reliably. Its solutions support applications ranging from power distribution and backup systems to industrial automation, building infrastructure and transportation.

The company’s Electrical segment provides products and systems such as circuit breakers, switchgear, power distribution equipment, surge protection, energy management software and data center power solutions.

Featured Stories Five stocks we like better than Eaton Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat

Receive News & Ratings for Eaton Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eaton and related companies with MarketBeat.com's FREE daily email newsletter.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Duolingo To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Duolingo between May 2, 2025 and February 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - October 24, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Duolingo, Inc. ("Duolingo" or the "Company") (NASDAQ: DUOL) and reminds investors of the December 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Daily Active User ("DAU") growth rates were being leveraged against deliberately added user friction in the form of significant increases in ad volume, subscription tier upsells, and worsened product quality, and defendants understood that any amount of user friction would cause users to leave the app and, ultimately, negatively impact DAU growth rates; (ii) Duolingo's rigorous A/B testing demonstrated to defendants that increased friction in the free user experience was having negative impacts on DAU growth rates; (iii) Duolingo's quickly generated AI content was worsening the quality of Duolingo's product offerings, negatively impacting the user experience and user trends, and threatening the sustainability of Duolingo's financial performance; and (iv) far from driving sustained growth and strong user momentum through content and "product improvements" that "get improved retention," Duolingo's constant A/B testing informed Duolingo that its monetization push and lower-quality, rapidly generated AI content were degrading the Duolingo product experience and the value proposition of its subscription tiers.

On November 5, 2025, the Company reported its third quarter ("3Q") financial results, revealing another sequential decline in DAU growth to 36%, a substantial drop from 49% in 1Q 2025 and 40% during 2Q 2025, and announced a long-term strategy change to pivot away from monetization and towards improving quality of teaching and prioritizing long-term DAU growth. On this news, Duolingo's stock price fell $66.28, or 25%, to close at $193.74 per share on November 6, 2025.

On January 12, 2026, Duolingo announced that its Chief Financial Officer ("CFO"), Matthew Skaruppa ("Skaruppa"), had resigned, and provided limited, preliminary fourth quarter ("4Q") 2025 operating metrics revealing DAU growth of only 30% - nearly six points of additional deceleration from 3Q 2025. On this news, Duolingo's stock price fell $14.92, or 8.5%, to close at $161.74 per share on January 12, 2026.

On February 26, 2026, after the market closed, Duolingo announced its 4Q 2025 financial results, confirmed the slowdown in DAU growth, and revealed material negative impacts on 2026 bookings, DAU growth rates, revenue, and adjusted EBITDA, with 2026 DAU growth guidance of only 20% accompanied by lower bookings and less profitability. On this news, Duolingo's stock price fell $16.45, or 14%, to close at $101 per share on February 27, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Duolingo's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Duolingo class action, go to www.faruqilaw.com/DUOL or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Duolingo Securities Class Action Lawsuit:

What is the Duolingo securities fraud lawsuit about?

The lawsuit alleges that Duolingo, Inc. made materially false and misleading statements during the Class Period regarding the company's daily active user ("DAU") growth and the drivers of its business performance. Specifically, the complaint alleges that defendants knew that deliberate increases in ad volume, subscription upsells, and other friction in the free user experience were negatively impacting DAU growth rates, a dynamic that Duolingo's own rigorous A/B testing allegedly confirmed. The lawsuit further alleges that rapidly generated AI content was worsening product quality and undermining the sustainability of Duolingo's financial performance, contrary to defendants' public statements touting content and product improvements as drivers of sustained growth and strong user retention. Investors allegedly were not told that Duolingo's internal testing had demonstrated these adverse trends until a series of corrective disclosures caused the company's stock price to decline significantly.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired Duolingo, Inc. (NASDAQ: DUOL) securities between May 2, 2025 and February 26, 2026, inclusive (the "Class Period"), may be eligible to participate in the lawsuit. Participation in the litigation is not limited to those who apply to serve as lead plaintiff; any eligible class member may share in any recovery that may be obtained on behalf of the class. Investors who believe they purchased Duolingo securities during the Class Period and suffered a loss are encouraged to review the complaint and consult with counsel to understand their rights and options.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation, including decisions about litigation strategy and any settlement. The lead plaintiff is typically the class member with the largest financial interest in the relief sought by the class who also meets certain adequacy and typicality requirements under the federal securities laws. Any investor who purchased Duolingo securities during the Class Period and wishes to seek appointment as lead plaintiff must file a motion with the court no later than the lead plaintiff deadline specified in the notice. Importantly, investors are not required to serve as lead plaintiff in order to be a member of the class or to share in any recovery that may result from the litigation.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Duolingo securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320198

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Brookstone Capital Management boosted its position in shares of Howmet Aerospace Inc. (NYSE: HWM) by 878.0% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,435 shares of the company's stock after acquiring an additional 34,505 shares during the quarter.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In D-Wave Quantum To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in D-Wave Quantum between February 26, 2026 and August 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - October 24, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against D-Wave Quantum Inc. ("D-Wave Quantum" or the "Company") (NASDAQ: QBTS) and reminds investors of the December 15, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants materially overstated D-Wave's business and financial prospects; (ii) the foregoing was reasonably likely to negatively impact the Company's business and reputation; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On August 6, 2026, D-Wave announced its financial results for the second quarter of 2026, reporting revenue of just $3.08 million, compared to $3.1 million for the same period in the prior year, falling short of analyst expectations ranging from $4.03 million to $4.08 million. On this news, D-Wave's stock price declined $1.99 per share, or 9.28%, to close at $19.41 per share on August 6, 2026.

On August 25, 2026, D-Wave issued a press release "announc[ing] that John Markovich is retiring and thus resigning from his position as Chief Financial Officer effective September 2, 2026." On this news, D-Wave's stock price fell $1.84 per share, or 9.51%, closing at $17.51 per share on August 26, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding D-Wave Quantum's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the D-Wave Quantum class action, go to www.faruqilaw.com/QBTS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the D-Wave Quantum Securities Class Action Lawsuit:

What is the D-Wave Quantum securities fraud lawsuit about?

The lawsuit alleges that D-Wave Quantum Inc. and certain of its officers and directors made materially false and misleading statements and/or failed to disclose material information during the Class Period. Specifically, the complaint alleges that Defendants materially overstated D-Wave's business and financial prospects, and that this alleged misrepresentation was reasonably likely to negatively impact the Company's business and reputation. As a result, the lawsuit alleges that Defendants' public statements were materially false and misleading at all relevant times during the Class Period. The action was filed on behalf of investors who suffered damages as a result of their reliance on those allegedly false and misleading statements.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired D-Wave Quantum Inc. (NASDAQ: QBTS) securities between February 26, 2026 and August 25, 2026, inclusive, may be eligible to participate in this lawsuit. Eligibility is not limited to those who seek appointment as lead plaintiff; any class member who suffered losses during the Class Period may potentially share in any recovery obtained. Investors are encouraged to review their trading records for the relevant period to assess whether they purchased QBTS securities during the Class Period. Faruqi & Faruqi, LLP invites potentially affected investors to contact the firm to discuss their legal rights and options.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a court-appointed representative who acts on behalf of all class members and plays an active role in directing the litigation, including working with counsel to make key strategic decisions in the case. Any investor who purchased D-Wave Quantum securities during the Class Period and suffered a loss may move the court for appointment as lead plaintiff by the applicable lead plaintiff deadline. Courts typically appoint the movant with the largest financial interest in the relief sought, provided that movant satisfies the relevant legal requirements. Importantly, investors need not serve as lead plaintiff to share in any recovery that may be obtained; class members who do not seek appointment may still participate in any settlement or judgment.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased D-Wave Quantum securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320199

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us